XERS Xeris Biopharma Holdings, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1867096 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY38.4%
TTM net income YoY58.5%
TTM EPS YoY70.0%
Revenue 3-yr CAGR34.1%
Net income 3-yr CAGR—
Margins
Gross margin87.4%
Operating margin12.7%
Net margin-1.8%
FCF margin—
EBITDA margin13.1%
Returns
ROE-27.1%
ROA-1.6%
ROIC (approx.)31.5%
Asset turnover0.93x
Leverage & solvency
Liabilities / assets88.5%
Debt / equity3.89x
Current ratio2.15x
Interest coverage1.70x
Cash quality & payout
Operating cash flow / net income-11.34x
Accruals ratio-20.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $107.22M | $92.10M | $83.13M | $85.81M | $74.38M | $71.54M | $60.12M | $60.10M |
| Cost of revenue | $12.43M | $12.51M | $10.57M | $10.95M | $11.00M | $11.90M | $8.73M | $9.48M |
| Gross profit | $94.80M | $79.59M | $72.55M | $74.86M | $63.38M | $59.64M | $51.39M | $50.62M |
| R&D expense | $11.06M | $10.67M | $8.78M | $7.87M | $7.48M | $8.05M | $7.75M | $6.09M |
| SG&A expense | $64.11M | $61.03M | $53.14M | $47.50M | $46.46M | $44.39M | $44.02M | $40.14M |
| Operating income | $16.92M | $5.17M | $7.92M | $16.77M | $6.73M | $4.48M | -$3.09M | $1.68M |
| Interest expense | $6.46M | $6.95M | $6.88M | $7.15M | $7.27M | $7.36M | $7.30M | $7.70M |
| Income tax | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Net income | $11.29M | -$31.10M | $2.23M | $11.08M | $621,000 | -$1.93M | -$9.22M | -$5.11M |
| EBITDA | $17.22M | $5.50M | $8.25M | $17.11M | $7.03M | $4.81M | -$2.77M | $1.99M |
| EPS (basic) | 0.06 | -0.18 | 0.01 | — | 0.00 | -0.01 | -0.06 | — |
| EPS (diluted) | 0.06 | -0.18 | 0.01 | — | 0.00 | -0.01 | -0.06 | — |
| Weighted avg. shares (diluted) | 189.92M | 172.82M | 177.63M | — | 177.62M | 159.46M | 152.45M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $131.08M | $121.75M | $111.75M | $111.04M | $91.60M | $59.28M | $58.44M | $75.74M |
| Short-term investments | — | — | — | — | — | — | — | $0 |
| Receivables | $68.60M | $58.10M | $56.30M | $51.05M | $53.75M | $53.05M | $46.33M | $40.41M |
| Inventory | $76.92M | $80.93M | $74.23M | $68.67M | $67.46M | $67.28M | $52.69M | $48.17M |
| Current assets | $289.26M | $274.76M | $251.68M | $240.31M | $224.02M | $185.58M | $163.49M | $167.66M |
| PP&E, net | $4.64M | $4.83M | $5.03M | $4.95M | $4.95M | $5.28M | $5.26M | $5.56M |
| Goodwill | $22.86M | $22.86M | $22.86M | $22.86M | $22.86M | $22.86M | $22.86M | $22.86M |
| Intangibles | $79.95M | $82.66M | $85.37M | $88.08M | $90.79M | $93.50M | $96.21M | $98.92M |
| Total assets | $423.22M | $411.90M | $392.01M | $383.53M | $370.19M | $334.69M | $315.45M | $323.06M |
| Current liabilities | $134.48M | $189.57M | $118.59M | $109.57M | $116.20M | $95.17M | $95.07M | $100.44M |
| Short-term debt | — | $63.78M | — | $0 | $0 | $0 | $11.96M | $15.10M |
| Long-term debt | $189.71M | $188.81M | $221.22M | $220.34M | $219.47M | $218.63M | $217.81M | $217.01M |
| Total debt | $189.71M | $252.59M | $221.22M | $220.34M | $219.47M | $218.63M | $229.76M | $232.11M |
| Total liabilities | $374.44M | $421.64M | $379.00M | $369.84M | $371.05M | $353.99M | $350.58M | $352.68M |
| Shareholders' equity | $48.78M | -$9.73M | $13.01M | $13.69M | -$861,000 | -$19.30M | -$35.13M | -$29.61M |
| Net debt | $58.63M | $130.84M | $109.47M | $109.29M | $127.87M | $159.34M | $171.32M | $156.36M |
| Shares outstanding | 182.57M | 173.59M | 172.56M | 166.22M | 165.53M | 161.22M | 156.01M | 149.43M |
| Cash flow statement | ||||||||
| Operating cash flow | $35.47M | $8.26M | $9.87M | $20.04M | $18.43M | $182,000 | -$10.03M | $1.98M |
| Investing cash flow | -$159,000 | -$209,000 | -$325,000 | -$333,000 | -$71,000 | -$279,000 | -$13,000 | $10.02M |
| Financing cash flow | -$25.98M | $1.94M | -$8.84M | -$266,000 | $13.85M | $942,000 | -$3.14M | $398,000 |
| Depreciation & amortization | $300,000 | $323,000 | $337,000 | $335,000 | $300,000 | $325,000 | $315,000 | $313,000 |
| Stock-based compensation | $10.80M | $11.07M | $4.14M | $5.27M | $7.64M | $5.01M | $4.44M | $3.60M |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.